Toronto-based psychedelic therapy company Reunion Neuroscience has entered an agreement with MPM BioImpact, a biotechnology investment firm, for an all-cash acquisition valued at approximately USD 13.1 million. The transaction will be carried out through a statutory plan of arrangement under the Canada Business Corporations Act. The acquisition is subject to shareholder approval and other conditions.
The acquisition by MPM BioImpact will provide Reunion Neuroscience with financial support and strategic partnership opportunities to advance the development of its clinical pipeline and address unmet medical needs in the field of mental health. The transaction is expected to close in Q3 2023.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.